MCL Literature Feed

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

A case report demonstrates that MCL can relapse in rare sites like skeletal muscle after rituximab maintenance, underscoring the value of PET/CT for detecting atypical disease progression.

This review details diverse BTKi resistance mechanisms beyond BTK mutations, providing a framework for developing next-generation inhibitors and combination strategies to overcome treatment failure in MCL.

Single-cell RNA sequencing reveals pre-existing, minor therapy-resistant subclones at diagnosis, which are selected during treatment, explaining early relapse and highlighting cell-cycle dysregulation as a common resistance mechanism.

In real-world relapsed/refractory MCL, ibrutinib dose reduction to manage toxicity is common and does not compromise response rates, PFS, or OS, validating this as a practical clinical strategy.

In a large real-world analysis, R-CHOP/R-DHAP trended toward better OS in transplant-eligible patients, while rituximab maintenance, not initial chemo, drove survival in transplant-ineligible patients.

PRMT5 inhibition sensitizes MCL cells to ferroptosis by disrupting the ATF5-SLC7A11 axis, providing a rationale for combining PRMT5 inhibitors with ferroptosis inducers for relapsed/refractory disease.

Single-cell multi-omics reveals genetic and non-genetic pirtobrutinib resistance mechanisms in MCL, identifying the cohesin complex as a potential target to restore drug sensitivity.

A deep learning model fusing PET/CT and EHR data creates a new signature that better predicts survival in frontline MCL, potentially improving risk-adapted therapy selection.

Consensus guidelines recommend the BOVen triplet (zanubrutinib, obinutuzumab, venetoclax) for TP53-mutated MCL and CAR-T for BTKi-refractory disease, providing expert guidance for managing high-risk patients.

This review outlines the evolving MCL treatment paradigm, detailing the integration of BTKi, CAR-T, and bispecific antibodies in both frontline and relapsed/refractory settings to improve patient outcomes.

This case report identifies a rare, aggressive MCL variant with blastoid morphology, TdT expression, and MYC rearrangement, broadening the known clinicopathological spectrum and posing significant diagnostic challenges.

A real-world, retrospective study demonstrates that clinical next-generation sequencing panels provide significant prognostic and predictive data in mantle cell lymphoma, aiding in the optimization of patient management.

This case report describes the rare co-occurrence of MCL and a pancreatic neuroendocrine tumor, highlighting a diagnostic pitfall where lymphadenopathy can originate from either malignancy, complicating staging.

Genomic analysis reveals MCL relapse is driven by the expansion of pre-existing resistant subclones, not new mutations, highlighting the need for deep sequencing at diagnosis to prevent recurrence.

This case report details severe, reversible myocarditis from bortezomib, a rare but critical cardiotoxicity for clinicians to recognize in MCL patients receiving proteasome inhibitor-based therapy.

CT-guided anterior approach biopsy is a safe and effective minimally invasive technique for diagnosing orbital lymphoma, including mantle cell lymphoma, providing an alternative to more invasive surgical procedures.

Preclinical data suggests PRMT5 inhibition is a promising combination therapy strategy for high-risk MCL with ATM and TP53 mutations, which are known to confer therapeutic resistance.

Mitochondrial ACSS1 enables nutrient-stressed B-cell lymphomas to produce DNA/RNA building blocks via acetate metabolism, identifying ACSS1 as a novel therapeutic target to overcome metabolic adaptation.

This retrospective analysis evaluates transplant outcomes in relapsed/refractory MCL after ibrutinib failure, identifying risk factors to guide patient selection for this intensive consolidation therapy.

This review contextualizes MCL-approved BTK inhibitors by summarizing their distinct covalent and non-covalent binding mechanisms, which underlie differences in efficacy, toxicity, and overcoming resistance.

This first real-world analysis of ASCT for MCL in Argentina confirms its efficacy but identifies blastoid variant, age ≥55, and high comorbidities as independent predictors of poor survival.

This large, real-world study demonstrates that any disease progression, even occurring more than 6 years after initial therapy, significantly worsens overall survival in mantle cell lymphoma.

This comprehensive review synthesizes emerging biomarkers beyond standard prognosticators, including MRD, ctDNA, and advanced imaging, to better guide personalized treatment in the targeted therapy era.

In a resource-limited setting, 12% of chemosensitive MCL patients progress by 3 months while awaiting autologous transplant, highlighting the need for prioritization and defining acceptable wait times.

Real-world data from Germany and Switzerland confirms the effectiveness of brexucabtagene-autoleucel in relapsed/refractory MCL, supporting its use in routine clinical practice beyond trial populations.

This review outlines evidence for sequencing BTKis, CAR-T, and bispecifics in relapsed/refractory MCL, a growing challenge as targeted therapies are increasingly used in the frontline setting.

This review describes the clinical presentation, diagnosis, and management of mantle cell lymphoma involving the gastrointestinal tract, a common site of extranodal disease requiring specific diagnostic consideration.

The lymph node microenvironment silences the pro-apoptotic protein BIM via a CD40/PI3K/FOXO1 axis, driving broad drug resistance that can be overcome by bispecific T-cell engager immunotherapy.